盆腔和腹部淋巴寡转移的SMART消融:临床与剂量学结果
前瞻性登记数据纳入26例患者31个寡进展淋巴转移灶,接受磁共振引导在线自适应放疗(SMART)。140次放疗中134次因预测计划违反计划目标而自适应,靶区覆盖中位数由89%升至95%,危及器官和靶区过量照射均减少。中位随访9.8个月,6个月无进展生存率63%,局部控制率97%,无≥3级毒性。
要点
- SMART使靶区覆盖中位数由预测计划89%提高至自适应计划95%(p<0.001)。
- 自适应计划使危及器官过量照射由27/140次降至1/140次(p<0.001)。
- 中位随访9.8个月,6个月局部控制率97%,无≥3级毒性报告。
核心结论
- SMART较非自适应放疗改善靶区覆盖并提供更优的危及器官保护,为再程放疗等挑战性病例提供创新方法。
研究设计与样本
- 前瞻性登记数据分析,纳入26例患者31个寡进展淋巴转移灶(1-2个病灶),于2020年4月至2021年4月接受SMART。
- 前列腺癌为最常见组织学类型(69%),63%患者既往接受过腹部盆腔放疗。
- SMART分3-7次给予,分次方案取决于计划靶区位置和既往剂量暴露。
主要发现
- 自适应主要因预测计划违反计划目标而执行(134/140次,96%)。
- 靶区覆盖提高:预测计划中位数89% vs 自适应计划中位数95%(p<0.001)。
- 危及器官过量照射减少:预测计划27/140次(19%) vs 自适应计划1/140次(1%)(p<0.001)。
- 靶区过量照射减少:预测计划21/140次(15%) vs 自适应计划1/140次(1%)(p<0.001)。
- 中位随访9.8个月,1例野内进展、12例野外进展;6个月无进展生存率63%(46-88%),局部控制率97%(90-100%)。
关键数值与推荐
- SMART流程:在每日3D磁共振成像上重新计算基线计划(预测计划),计划目标违反时强制进行计划自适应。
- 分次方案为3-7次,依据计划靶区位置和既往剂量暴露确定。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To demonstrate dosimetry benefits and report clinical outcomes of stereotactic magnetic resonance (MR)-guided online adaptive radiotherapy (SMART) of abdominopelvic lymphatic oligometastases. PATIENTS & METHODS: Prospective registry data of 26 patients with 31 oligoprogressive lymphatic metastases (1-2 lesions) who received SMART between April 2020 and April 2021 was analyzed. Prostate cancer was the most common histology (69%). Most patients (63%) had received previous abdominopelvic radiotherapy (RT). SMART was delivered in 3-7 fractions based on planning target volume (PTV) location and previous dose exposures. For SMART, the baseline plan was recalculated on daily 3D MR-imaging (predicted plan), and plan adaptation was mandatory in case of planning objective violations. RESULTS: Plan adaptation was mostly performed due to violation of planning objectives in the predicted plan (134/140 fractions, 96%) and significantly improved plan dosimetry: (1) PTV coverage was increased (predicted: median 89%, adapted: median 95%, p < 0.001), (2) organs-at-risk (OAR) overdoses were reduced (predicted: 27/140 (19%), adapted: 1/140 (1%), p < 0.001) and (3) PTV overdoses were reduced (predicted: 21/140 (15%), adapted: 1/140 (1%), p < 0.001). After a median follow-up of 9.8 months, one patient had in-field tumor progression and twelve patients had out-field tumor progression (at 6 months: progression-free survival: 63% [46-88%], local control rate: 97% [90-100%]). Treatment was tolerated well and no grade ≥3 toxicity was reported. CONCLUSION: SMART improves target volume coverage and yields superior OAR protection compared to non-adaptive radiotherapy, thus representing an innovative approach to challenging cases, such as repeated radiotherapy.
引用
- Regnery S, Buchele C, Piskorski L, et al. SMART ablation of lymphatic oligometastases in the pelvis and abdomen: Clinical and dosimetry outcomes. Radiother Oncol. 2022. PMID: 35121031. doi:10.1016/j.radonc.2022.01.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。